Research ExplorerJournalsLANCET Publications

LANCET

1 - 50 out of 108Page size: 50

Publications

  1. 2024

  2. Persistent physical symptoms: definition, genesis, and management

    Löwe, B., Toussaint, A-K., Rosmalen, J. G. M., Huang, W-L., Burton, C., Weigel, A., Levenson, J. & Henningsen, P., 15.06.2024, In: LANCET. 403, 10444, p. 2649-2662 14 p.

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  3. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

    GBD 2021 Risk Factors Collaborators, 18.05.2024, In: LANCET. 403, 10440, p. 2162-2203 42 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  4. 2023

  5. Efficacy of rocatinlimab for moderate-to-severe atopic dermatitis - Authors' reply

    Guttman-Yassky, E., Simpson, E. L., Reich, K., Kabashima, K., Igawa, K., Suzuki, T., Mano, H., Matsui, T., Esfandiari, E. & Furue, M., 18.11.2023, In: LANCET. 402, 10415, p. 1834

    Research output: SCORING: Contribution to journal › Comment/debate › Research

  6. Endovascular thrombectomy for acute ischaemic stroke with established large infarct: multicentre, open-label, randomised trial

    Bendszus, M., Fiehler, J., Subtil, F., Bonekamp, S., Aamodt, A. H., Fuentes, B., Gizewski, E. R., Hill, M. D., Krajina, A., Pierot, L., Simonsen, C. Z., Zeleňák, K., Blauenfeldt, R. A., Cheng, B., Denis, A., Deutschmann, H., Dorn, F., Flottmann, F., Gellißen, S., Gerber, J. C., Goyal, M., Haring, J., Herweh, C., Hopf-Jensen, S., Hua, V. T., Jensen, M., Kastrup, A., Keil, C. F., Klepanec, A., Kurča, E., Mikkelsen, R., Möhlenbruch, M., Müller-Hülsbeck, S., Münnich, N., Pagano, P., Papanagiotou, P., Petzold, G. C., Pham, M., Puetz, V., Raupach, J., Reimann, G., Ringleb, P. A., Schell, M., Schlemm, E., Schönenberger, S., Tennøe, B., Ulfert, C., Vališ, K., Vítková, E., Vollherbst, D. F., Wick, W., Thomalla, G. & TENSION Investigators, 11.11.2023, In: LANCET. 402, 10414, p. 1753-1763 11 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  7. AATD as a genetic risk factor for aneurysmal disease - Authors' reply

    von Kodolitsch, Y., Kubisch, C. & Carrel, T., 04.11.2023, In: LANCET. 402, 10413, p. 1626 1 p.

    Research output: SCORING: Contribution to journal › Comment/debate › Research

  8. Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial

    Khanani, A. M., Patel, S. S., Staurenghi, G., Tadayoni, R., Danzig, C. J., Eichenbaum, D. A., Hsu, J., Wykoff, C. C., Heier, J. S., Lally, D. R., Monés, J., Nielsen, J. S., Sheth, V. S., Kaiser, P. K., Clark, J., Zhu, L., Patel, H., Tang, J., Desai, D., Jaffe, G. J. & GATHER2 trial investigators, 21.10.2023, In: LANCET. 402, 10411, p. 1449-1458 10 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  9. Acute aortic dissection

    Carrel, T., Sundt, T. M., von Kodolitsch, Y. & Czerny, M., 04.03.2023, In: LANCET. 401, 10378, p. 773-788 16 p.

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  10. An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis:a multicentre, double-blind, placebo-controlled phase 2b study

    Guttman-Yassky, E., Simpson, E. L., Reich, K., Kabashima, K., Igawa, K., Suzuki, T., Mano, H., Matsui, T., Esfandiari, E. & Furue, M., 21.01.2023, In: LANCET. 401, 10372, p. 204-214 11 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  11. 2022

  12. Bacterial infection possibly causing autoimmunity: Tropheryma whipplei and membranous nephropathy

    Wiech, T., Reinhard, L., Wulf, S., Giuffrida, A. E., Longhitano, E., Caruso, R., Gröne, H-J., Stahl, R. A. K., Zipfel, P. F., Kikhney, J., Moter, A., Hoxha, E. & Santoro, D., 26.11.2022, In: LANCET. 400, 10366, p. 1882-1883 2 p.

    Research output: SCORING: Contribution to journal › Other (editorial matter etc.) › Research

  13. Elective surgery system strengthening: development, measurement, and validation of the surgical preparedness index across 1632 hospitals in 119 countries

    COVIDSurg Collaborative, 05.11.2022, In: LANCET. 400, 10363, p. 1607-1617 11 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  14. Artificial intelligence for early atrial fibrillation detection

    Fabritz, L. & Obergassel, J., 08.10.2022, In: LANCET. 400, 10359, p. 1173-1175 3 p.

    Research output: SCORING: Contribution to journal › Comment/debate › Research

  15. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial

    Reich, K., Thyssen, J. P., Blauvelt, A., Eyerich, K., Soong, W., Rice, Z. P., Hong, H. C-H., Katoh, N., Valenzuela, F., DiBonaventura, M., Bratt, T. A., Zhang, F., Clibborn, C., Rojo, R., Valdez, H. & Kerkmann, U., 23.07.2022, In: LANCET. 400, 10348, p. 273-282 10 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  16. The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality

    Karlsen, T. H., Sheron, N., Zelber-Sagi, S., Carrieri, P., Dusheiko, G., Bugianesi, E., Pryke, R., Hutchinson, S. J., Sangro, B., Martin, N. K., Cecchini, M., Dirac, M. A., Belloni, A., Serra-Burriel, M., Ponsioen, C. Y., Sheena, B., Lerouge, A., Devaux, M., Scott, N., Hellard, M., Verkade, H. J., Sturm, E., Marchesini, G., Yki-Järvinen, H., Byrne, C. D., Targher, G., Tur-Sinai, A., Barrett, D., Ninburg, M., Reic, T., Taylor, A., Rhodes, T., Treloar, C., Petersen, C., Schramm, C., Flisiak, R., Simonova, M. Y., Pares, A., Johnson, P., Cucchetti, A., Graupera, I., Lionis, C., Pose, E., Fabrellas, N., Ma, A. T., Mendive, J. M., Mazzaferro, V., Rutter, H., Cortez-Pinto, H., Kelly, D., Burton, R., Lazarus, J. V., Ginès, P., Buti, M., Newsome, P. N., Burra, P., Manns, M. P. & EASL Lancet Commission, 01.01.2022, In: LANCET. 399, 10319, p. 61-116 56 p.

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  17. 2021

  18. Late presentation of hepatocellular carcinoma highlights the need for a public health programme to eliminate hepatitis B

    Nhlane, R., Kreuels, B., Mallewa, J., Chetcuti, K., Gordon, M. A. & Stockdale, A. J., 18.12.2021, In: LANCET. 398, 10318, 2288.

    Research output: SCORING: Contribution to journal › Other (editorial matter etc.) › Research

  19. Second asymptomatic carotid surgery trial (ACST-2): a randomised comparison of carotid artery stenting versus carotid endarterectomy

    Halliday, A., Bulbulia, R., Bonati, L. H., Chester, J., Cradduck-Bamford, A., Peto, R., Pan, H. & ACST-2 Collaborative Group, 18.09.2021, In: LANCET. 398, 10305, p. 1065-1073 9 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  20. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study

    Sun, J-M., Shen, L., Shah, M. A., Enzinger, P., Adenis, A., Doi, T., Kojima, T., Metges, J-P., Li, Z., Kim, S-B., Cho, B. C., Mansoor, W., Li, S-H., Sunpaweravong, P., Maqueda, M. A., Goekkurt, E., Hara, H., Antunes, L., Fountzilas, C., Tsuji, A., Oliden, V. C., Liu, Q., Shah, S., Bhagia, P., Kato, K. & KEYNOTE-590 Investigators, 28.08.2021, In: LANCET. 398, 10302, p. 759-771 13 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  21. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial

    Reich, K., Teixeira, H. D., de Bruin-Weller, M., Bieber, T., Soong, W., Kabashima, K., Werfel, T., Zeng, J., Huang, X., Hu, X., Hendrickson, B. A., Ladizinski, B., Chu, A. D. & Silverberg, J. I., 05.06.2021, In: LANCET. 397, 10290, p. 2169-2181 13 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  22. IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study

    Papp, K. A., Weinberg, M. A., Morris, A. & Reich, K., 24.04.2021, In: LANCET. 397, 10284, p. 1564-1575 12 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  23. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial

    Gordon, K. B., Foley, P., Krueger, J. G., Pinter, A., Reich, K., Vender, R., Vanvoorden, V., Madden, C., White, K., Cioffi, C. & Blauvelt, A., 06.02.2021, In: LANCET. 397, 10273, p. 475-486 12 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  24. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial

    Reich, K., Papp, K. A., Blauvelt, A., Langley, R. G., Armstrong, A., Warren, R. B., Gordon, K. B., Merola, J. F., Okubo, Y., Madden, C., Wang, M., Cioffi, C., Vanvoorden, V. & Lebwohl, M., 06.02.2021, In: LANCET. 397, 10273, p. 487-498 12 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  25. Neuropathology associated with SARS-CoV-2 infection

    Glatzel, M., Hagel, C., Matschke, J., Sperhake, J., Deigendesch, N., Tzankov, A. & Frank, S., 23.01.2021, In: LANCET. 397, 10271, p. 276

    Research output: SCORING: Contribution to journal › Other (editorial matter etc.) › Research

  26. 2020

  27. Association of SARS-CoV-2 renal tropism with acute kidney injury - Authors' reply

    Braun, F., Edler, C., Puelles, V. G. & Huber, T. B., 12.12.2020, In: LANCET. 396, 10266, p. 1881-1882 2 p.

    Research output: SCORING: Contribution to journal › Other (editorial matter etc.) › Research

  28. Intravenous alteplase for stroke with unknown time of onset guided by advanced imaging: systematic review and meta-analysis of individual patient data

    Thomalla, G., Boutitie, F., Ma, H., Koga, M., Ringleb, P., Schwamm, L. H., Wu, O., Bendszus, M., Bladin, C. F., Campbell, B. C. V., Cheng, B., Churilov, L., Ebinger, M., Endres, M., Fiebach, J. B., Fukuda-Doi, M., Inoue, M., Kleinig, T. J., Latour, L. L., Lemmens, R., Levi, C. R., Leys, D., Miwa, K., Molina, C. A., Muir, K. W., Nighoghossian, N., Parsons, M. W., Pedraza, S., Schellinger, P. D., Schwab, S., Simonsen, C. Z., Song, S. S., Thijs, V., Toni, D., Hsu, C. Y., Wahlgren, N., Yamamoto, H., Yassi, N., Yoshimura, S., Warach, S., Hacke, W., Toyoda, K., Donnan, G. A., Davis, S. M., Gerloff, C. & Evaluation of unknown Onset Stroke thrombolysis trials (EOS) investigators, 14.11.2020, In: LANCET. 396, 10262, p. 1574-1584 11 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  29. Timing of radiotherapy after radical prostatectomy

    Tilki, D. & D'Amico, A. V., 31.10.2020, In: LANCET. 396, 10260, p. 1374-1375 2 p.

    Research output: SCORING: Contribution to journal › Other (editorial matter etc.) › Research

  30. Long-term efficacy and safety of drug-coated balloons versus drug-eluting stents for small coronary artery disease (BASKET-SMALL 2): 3-year follow-up of a randomised, non-inferiority trial

    Jeger, RV., Farah, A., Ohlow, MA., Mangner, N., Möbius-Winkler, S., Weilenmann, D., Wöhrle, J., Stachel, G., Markovic, S., Leibundgut, G., Rickenbacher, P., Osswald, S., Cattaneo, M., Gilgen, N., Kaiser, C., Scheller, B. & BASKET-SMALL 2 Investigators, 10.2020, In: LANCET. 396, 10261, p. 1504-1510 7 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  31. SARS-CoV-2 renal tropism associates with acute kidney injury

    Braun, F., Lütgehetmann, M., Pfefferle, S., Wong, M. N., Carsten, A., Lindenmeyer, M. T., Nörz, D., Heinrich, F., Meißner, K., Wichmann, D., Kluge, S., Gross, O., Pueschel, K., Schröder, A. S., Edler, C., Aepfelbacher, M., Puelles, V. G. & Huber, T. B., 29.08.2020, In: LANCET. 396, 10251, p. 597-598 2 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  32. Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial

    SEMIRA collaborators, 25.07.2020, In: LANCET. 396, 10246, p. 267-276 10 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  33. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study

    Dimopoulos, M., Quach, H., Mateos, M-V., Landgren, O., Leleu, X., Siegel, D., Weisel, K., Yang, H., Klippel, Z., Zahlten-Kumeli, A. & Usmani, S. Z., 18.07.2020, In: LANCET. 396, 10245, p. 186-197 12 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  34. COVID-19-associated nephritis: early warning for disease severity and complications?

    Gross, O., Moerer, O., Weber, M., Huber, T. B. & Scheithauer, S., 16.05.2020, In: LANCET. 395, 10236, p. e87-e88

    Research output: SCORING: Contribution to journal › Other (editorial matter etc.) › Research

  35. An international registry for emergent pathogens and pregnancy

    Panchaud, A., Favre, G., Pomar, L., Vouga, M., Aebi-Popp, K., Baud, D. & COVI-Preg group, 09.05.2020, In: LANCET. 395, 10235, p. 1483-1484 2 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  36. Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial

    Phillips, R. O., Robert, J., Abass, K. M., Thompson, W., Sarfo, F. S., Wilson, T., Sarpong, G., Gateau, T., Chauty, A., Omollo, R., Ochieng Otieno, M., Egondi, T. W., Ampadu, E. O., Agossadou, D., Marion, E., Ganlonon, L., Wansbrough-Jones, M., Grosset, J., Macdonald, J. M., Treadwell, T., Saunderson, P., Paintsil, A., Lehman, L., Frimpong, M., Sarpong, N. F., Saizonou, R., Tiendrebeogo, A., Ohene, S-A., Stienstra, Y., Asiedu, K. B., van der Werf, T. S. & study team, 18.04.2020, In: LANCET. 395, 10232, p. 1259-1267 9 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research

  37. Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial

    Hill, M. D., Goyal, M., Menon, B. K., Nogueira, R. G., McTaggart, R. A., Demchuk, A. M., Poppe, A. Y., Buck, B. H., Field, T. S., Dowlatshahi, D., van Adel, B. A., Swartz, R. H., Shah, R. A., Sauvageau, E., Zerna, C., Ospel, J. M., Joshi, M., Almekhlafi, M. A., Ryckborst, K. J., Lowerison, M. W., Heard, K., Garman, D., Haussen, D., Cutting, S. M., Coutts, S. B., Roy, D., Rempel, J. L., Rohr, A. C., Iancu, D., Sahlas, D. J., Yu, A. Y. X., Devlin, T. G., Hanel, R. A., Puetz, V., Silver, F. L., Campbell, B. C. V., Chapot, R., Teitelbaum, J., Mandzia, J. L., Kleinig, T. J., Turkel-Parrella, D., Heck, D., Kelly, M. E., Bharatha, A., Bang, O. Y., Jadhav, A., Gupta, R., Frei, D. F., Tarpley, J. W., McDougall, C. G., Holmin, S., Rha, J-H., Puri, A. S., Camden, M-C., Thomalla, G., Choe, H., Phillips, S. J., Schindler, J. L., Thornton, J., Nagel, S., Heo, J. H., Sohn, S-I., Psychogios, M-N., Budzik, R. F., Starkman, S., Martin, C. O., Burns, P. A., Murphy, S., Lopez, G. A., English, J., Tymianski, M. & ESCAPE-NA1 Investigators, 14.03.2020, In: LANCET. 395, 10227, p. 878-887 10 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  38. 2019

  39. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial

    Poeschel, V., Held, G., Ziepert, M., Witzens-Harig, M., Holte, H., Thurner, L., Borchmann, P., Viardot, A., Soekler, M., Keller, U., Schmidt, C., Truemper, L., Mahlberg, R., Marks, R., Hoeffkes, H-G., Metzner, B., Dierlamm, J., Frickhofen, N., Haenel, M., Neubauer, A., Kneba, M., Merli, F., Tucci, A., de Nully Brown, P., Federico, M., Lengfelder, E., di Rocco, A., Trappe, R., Rosenwald, A., Berdel, C., Maisenhoelder, M., Shpilberg, O., Amam, J., Christofyllakis, K., Hartmann, F., Murawski, N., Stilgenbauer, S., Nickelsen, M., Wulf, G., Glass, B., Schmitz, N., Altmann, B., Loeffler, M., Pfreundschuh, M. & FLYER Trial Investigators, 21.12.2019, In: LANCET. 394, 10216, p. 2271-2281 11 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  40. Application of non-HDL cholesterol for population-based cardiovascular risk stratification - results from the Multinational Cardiovascular Risk Consortium

    Brunner, F. J., Waldeyer, C., Ojeda, F., Salomaa, V., Kee, F., Sans, S., Thorand, B., Giampaoli, S., Brambilla, P., Tunstall-Pedoe, H., Moitry, M., Iacoviello, L., Veronesi, G., Grassi, G., Mathiesen, E. B., Söderberg, S., Linneberg, A., Brenner, H., Amouyel, P., Ferrières, J., Tamosiunas, A., Nikitin, Y. P., Drygas, W., Melander, O., Jöckel, K-H., Leistner, D. M., Shaw, J. E., Panagiotakos, D. B., Simons, L. A., Kavousi, M., Vasan, R. S., Dullaart, R. P. F., Wannamethee, S. G., Risérus, U., Shea, S., de Lemos, J. A., Omland, T., Kuulasmaa, K., Landmesser, U., Blankenberg, S. & Multinational Cardiovascular Risk Consortium, 14.12.2019, In: LANCET. 394, 10215, p. 2173-2183 11 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  41. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

    Younossi, Z. M., Ratziu, V., Loomba, R., Rinella, M., Anstee, Q. M., Goodman, Z., Bedossa, P., Geier, A., Beckebaum, S., Newsome, P. N., Sheridan, D., Sheikh, M. Y., Trotter, J., Knapple, W., Lawitz, E., Abdelmalek, M. F., Kowdley, K. V., Montano-Loza, A. J., Boursier, J., Mathurin, P., Bugianesi, E., Mazzella, G., Olveira, A., Cortez-Pinto, H., Graupera, I., Orr, D., Gluud, L. L., Dufour, J-F., Shapiro, D., Campagna, J., Zaru, L., MacConell, L., Shringarpure, R., Harrison, S., Sanyal, A. J. & REGENERATE Study Investigators, 14.12.2019, In: LANCET. 394, 10215, p. 2184-2196 13 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  42. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial

    Reich, K., Armstrong, A. W., Langley, R. G., Flavin, S., Randazzo, B., Li, S., Hsu, M-C., Branigan, P. & Blauvelt, A., 07.09.2019, In: LANCET. 394, 10201, p. 831-839 9 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  43. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial

    Reich, K., Gooderham, M., Thaçi, D., Crowley, J. J., Ryan, C., Krueger, J. G., Tsai, T-F., Flack, M., Gu, Y., Williams, D. A., Thompson, E. H. Z. & Paul, C., 17.08.2019, In: LANCET. 394, 10198, p. 576-586 11 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  44. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

    Al-Batran, S-E., Homann, N., Pauligk, C., Goetze, T. O., Meiler, J., Kasper, S., Kopp, H-G., Mayer, F., Haag, G. M., Luley, K., Lindig, U., Schmiegel, W., Pohl, M., Stoehlmacher, J., Folprecht, G., Probst, S., Prasnikar, N., Fischbach, W., Mahlberg, R., Trojan, J., Koenigsmann, M., Martens, U. M., Thuss-Patience, P., Egger, M., Block, A., Heinemann, V., Illerhaus, G., Moehler, M., Schenk, M., Kullmann, F., Behringer, D. M., Heike, M., Pink, D., Teschendorf, C., Löhr, C., Bernhard, H., Schuch, G., Rethwisch, V., von Weikersthal, L. F., Hartmann, J. T., Kneba, M., Daum, S., Schulmann, K., Weniger, J., Belle, S., Gaiser, T., Oduncu, F. S., Güntner, M., Hozaeel, W., Reichart, A., Jäger, E., Kraus, T., Mönig, S., Bechstein, W. O., Schuler, M., Schmalenberg, H., Hofheinz, R. D. & FLOT4-AIO Investigators, 11.05.2019, In: LANCET. 393, 10184, p. 1948-1957 10 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  45. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

    Dimopoulos, M. A., Gay, F., Schjesvold, F., Beksac, M., Hajek, R., Weisel, K. C., Goldschmidt, H., Maisnar, V., Moreau, P., Min, C. K., Pluta, A., Chng, W-J., Kaiser, M., Zweegman, S., Mateos, M-V., Spencer, A., Iida, S., Morgan, G., Suryanarayan, K., Teng, Z., Skacel, T., Palumbo, A., Dash, A. B., Gupta, N., Labotka, R., Rajkumar, S. V. & TOURMALINE-MM3 study group, 19.01.2019, In: LANCET. 393, 10168, p. 253-264 12 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  46. 2018

  47. PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group

    Borchmann, P., Goergen, H., Kobe, C., Lohri, A., Greil, R., Eichenauer, D. A., Zijlstra, J. M., Markova, J., Meissner, J., Feuring-Buske, M., Hüttmann, A., Dierlamm, J., Soekler, M., Beck, H-J., Willenbacher, W., Ludwig, W-D., Pabst, T., Topp, M. S., Hitz, F., Bentz, M., Keller, U. B., Kühnhardt, D., Ostermann, H., Schmitz, N., Hertenstein, B., Aulitzky, W., Maschmeyer, G., Vieler, T., Eich, H., Baues, C., Stein, H., Fuchs, M., Kuhnert, G., Diehl, V., Dietlein, M. & Engert, A., 23.12.2018, In: LANCET. 390, 10114, p. 2790-2802 13 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  48. Current practice and future directions in the diagnosis and acute treatment of ischaemic stroke

    Zerna, C., Thomalla, G., Campbell, B. C. V., Rha, J-H. & Hill, M. D., 06.10.2018, In: LANCET. 392, 10154, p. 1247-1256 10 p.

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  49. Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial

    Koehler, F., Koehler, K., Deckwart, O., Prescher, S., Wegscheider, K., Kirwan, B-A., Winkler, S., Vettorazzi, E., Bruch, L., Oeff, M., Zugck, C., Doerr, G., Naegele, H., Störk, S., Butter, C., Sechtem, U., Angermann, C., Gola, G., Prondzinsky, R., Edelmann, F., Spethmann, S., Schellong, S. M., Schulze, P. C., Bauersachs, J., Wellge, B., Schoebel, C., Tajsic, M., Dreger, H., Anker, S. D. & Stangl, K., 22.09.2018, In: LANCET. 392, 10152, p. 1047-1057 11 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  50. Diagnosing myocardial infarction: a highly sensitive issue

    Blankenberg, S., Neumann, J. T. & Westermann, D., 15.09.2018, In: LANCET. 392, 10151, p. 893-894 2 p.

    Research output: SCORING: Contribution to journal › Other (editorial matter etc.) › Research

  51. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

    Gordon, K. B., Strober, B., Lebwohl, M., Augustin, M., Blauvelt, A., Poulin, Y., Papp, K. A., Sofen, H., Puig, L., Foley, P., Ohtsuki, M., Flack, M., Geng, Z., Gu, Y., Valdes, J. M., Thompson, E. H. Z. & Bachelez, H., 25.08.2018, In: LANCET. 392, 10148, p. 650-661 12 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  52. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

    Shitara, K., Özgüroğlu, M., Bang, Y-J., Bartolomeo, M. D., Mandalà, M., Ryu, M-H., Fornaro, L., Olesiński, T., Caglevic, C., Chung, H. C., Muro, K., Goekkurt, E., Mansoor, W., McDermott, R. S., Shacham-Shmueli, E., Chen, X., Mayo, C., Kang, S. P., Ohtsu, A., Fuchs, C. S. & KEYNOTE-061 investigators, 14.07.2018, In: LANCET. 392, 10142, p. 123-133 11 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  53. Primary sclerosing cholangitis

    Dyson, J. K., Beuers, U., Jones, D. E. J., Lohse, A. W. & Hudson, M., 23.06.2018, In: LANCET. 391, 10139, p. 2547-2559 13 p.

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  54. Schistosomiasis detected during appendectomy

    Kraef, C., Arand, J., Veletzky, L., Schäfer, H., Jordan, S., Schmiedel, S. & Ramharter, M., 23.06.2018, In: LANCET. 391, 10139, p. 2546

    Research output: SCORING: Contribution to journal › Other (editorial matter etc.) › Research

  55. 2017

  56. Compassionate use of the PASCAL transcatheter mitral valve repair system for patients with severe mitral regurgitation: a multicentre, prospective, observational, first-in-man study

    Praz, F., Spargias, K., Chrissoheris, M., Büllesfeld, L., Nickenig, G., Deuschl, F., Schueler, R., Fam, N. P., Moss, R., Makar, M., Boone, R., Edwards, J., Moschovitis, A., Kar, S., Webb, J., Schäfer, U., Feldman, T. & Windecker, S., 19.08.2017, In: LANCET. 390, 10096, p. 773-780 8 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  57. Prevention of incisional hernia with prophylactic onlay and sublay mesh reinforcement versus primary suture only in midline laparotomies (PRIMA): 2-year follow-up of a multicentre, double-blind, randomised controlled trial

    PRIMA Trialist Group, 05.08.2017, In: LANCET. 390, 10094, p. 567-576 10 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  58. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial

    European Study Group for Pancreatic Cancer, 11.03.2017, In: LANCET. 389, 10073, p. 1011-1024 14 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Previous 1 2 3 Next